Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report.

International journal of surgical pathology - 1 Sept 2017

Shelekhova Ksenya V, Zhuravlev Alexander S, Krylova Daria D, Konstantinov Alexey S, Shtan Lidia V, Kheinshtein Valeriia A

Abstract excerpt

Only 28 cases of pseudomyxoma peritonei (PMP) arising from urachal neoplasms have been reported. We report one example of this extremely rare disease with KRAS mutational status in its spectrum of pathology. A 45-year-old woman presented with urachal frankly invasive mucinous cystadenocarcinoma confined to the dome of the bladder, which clinically manifested as PMP and was not detected at the first surgery. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to CDX2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Mutation

Share to Peritoneal Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 28449606
DOI: 10.1177/1066896917707041

Genes

KRAS
CDX2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report.PMID 28449606Read ↗

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.Semantic proximity Read ↗

A case of Pseudomyxoma Peritonei of an unexpected origin.Semantic proximity Read ↗

Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.Semantic proximity Read ↗

Rare Occurrence of Pseudomyxoma Peritonei (PMP) Syndrome Arising from a Malignant Transformed Ovarian Primary Mature Cystic Teratoma Treated by Cytoreductive Surgery and HIPEC: A Case ReportSemantic proximity Read ↗

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.Semantic proximity Read ↗

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.Semantic proximity Read ↗

Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.Semantic proximity Read ↗

Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.Semantic proximity Read ↗

Case Report: Bladder adenocarcinoma: primary or urachal?Semantic proximity Read ↗

Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.Semantic proximity Read ↗

Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.Semantic proximity Read ↗

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.